Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma

被引：6
|
作者：
Wang, Xiaoli [1 ]
Wu, Jingjing [1 ]
Zhang, Mingzhi [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Henan, Peoples R China
来源：
HEMATOLOGY | 2019年 / 24卷 / 01期
关键词：
Anaplastic large cell lymphoma; anaplastic lymphoma kinase; treatment; prognosis; PIVOTAL PHASE-II; BRENTUXIMAB VEDOTIN; OPEN-LABEL; ALK; DISEASE; TRANSPLANTATION; MULTICENTER; DOXORUBICIN; ADULTS; ERA;
D O I：
10.1080/16078454.2019.1613290
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK- ALCL) is a definite entity in the WHO 2016 Classification that represents 2-3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL). Some studies indicate that ALK- ALCL and ALK+ ALCL possess different molecular and genetic characteristics. Besides, ALK- ALCL is worse than ALK+ ALCL in terms of treatment outcome, prognosis, and long-term survival. This review is aimed at summarizing information about ALK- ALCL, especially with respect to the treatment and prognosis.
引用
收藏
页码：440 / 445
页数：6
相关论文
共 50 条
  • [41] Anaplastic Large Cell Lymphoma in Children and Adolescents
    Lowe, Eric J.
    Gross, Thomas G.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2013, 30 (06) : 509 - 519
  • [42] Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
    Cheng, Mangeng
    Ott, Gregory R.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (03) : 236 - 249
  • [43] Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
    Minich, Stephanie S.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 377 - 383
  • [44] Genetics of anaplastic large cell lymphoma
    Zeng, Yu
    Feldman, Andrew L.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 21 - 27
  • [45] Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma
    Melchers, Rutger C.
    Willemze, Rein
    van de Loo, Merel
    van Doorn, Remco
    Jansen, Patty M.
    Cleven, Arjen H. G.
    Solleveld, Nienke
    Bekkenk, Marcel W.
    van Kester, Marloes S.
    Diercks, Gillis F. H.
    Vermeer, Maarten H.
    Quint, Koen D.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (06) : 776 - 781
  • [46] Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: A case report
    Kothari S.
    Ud-Din N.
    Lisi M.
    Coyle T.
    Journal of Medical Case Reports, 10 (1)
  • [47] From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK plus ALCL)
    Werner, Michael T.
    Zhang, Qian
    Wasik, Mariusz A.
    CANCERS, 2017, 9 (10):
  • [48] Update on the Treatment of Anaplastic Large Cell Lymphoma
    Khoan Vu
    Weiyun Ai
    Current Hematologic Malignancy Reports, 2018, 13 : 135 - 141
  • [49] Large cell anaplastic lymphoma
    Yavorkovsky, LI
    Nikulshin, SV
    Leiniece, S
    Klutse, G
    EXPERIMENTAL ONCOLOGY, 1995, 17 (03): : 172 - 182
  • [50] PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature
    Arun, Indu
    Roy, Paromita
    Arora, Neeraj
    Bhave, Saurabh Jayant
    Nair, Reena
    Chandy, Mammen
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2017, 25 (04) : 333 - 338
12345